Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
March 9, 2021
Assignee:
THE TEXAS A&M UNIVERSITY SYSTEM
Inventors:
Thomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams, Angela M. Arenas-Gamboa
Abstract: The present invention provides biomarkers, methods and kits for diagnosing latent tuberculosis (TB) in a subject exposed to TB, and methods and kits for monitoring the effectiveness of treatment for latent TB.
Type:
Grant
Filed:
January 14, 2019
Date of Patent:
March 2, 2021
Assignees:
Caption Biosciences Inc., Case Western Reserve University
Inventors:
Eustache Paramithiotis, W. Henry Boom, Charles Bark
Abstract: Provided herein are alpha hemolysin polypeptides comprising modified amino acid sequences that can reduce the rate of translocation of a polymer. Also provided herein are apparatuses and devices comprising modified hemolysin polypeptides. Also provided herein are methods of using modified alpha hemolysin proteins for use in characterizing and/or sequencing a polymer or for use as molecular sensors.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
February 2, 2021
Assignee:
ELECTRONIC BIOSCIENCES, INC.
Inventors:
Geoffrey A. Barrall, Eric N. Ervin, Prithwish Pal
Abstract: Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with P. copri or a portion thereof. In one aspect of the invention the immunological reactivity of the subject to one or more protein of P. copri or polypeptide fragments thereof such as protein Pc-p27 or polypeptide fragments thereof, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays and kits for use with the methods are also disclosed.
Abstract: This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.
Abstract: Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.
Abstract: The present invention relates to a method capable of detecting, identifying or counting microorganisms, and a system using the same, and provides a method capable of identifying, detecting or counting microorganisms in a more rapid, accurate and convenient manner than a conventional method for identifying, detecting or counting microorganisms. According to the present invention, it was found that identification, detection or counting of microorganisms can be performed in a rapid, accurate and convenient manner, when a fluorescently labeled microorganism sample is centrifuged and attached to the surface of a slide, followed by analysis of fluorescent images. Therefore, the method and system of the present invention can be useful in various fields requiring detection, identification and counting of microorganisms.
Abstract: An isolated monoclonal antibody or antigen-binding fragment thereof binds to F. tularensis lipopolysaccharide (Ft LPS). The antibody preferably lacks an Fc region or has an impaired Fc-region. The antibody may be formulated into a pharmaceutical composition along with a pharmaceutically acceptable carrier, excipient or diluent. It may be provided in a kit with means for detection of the antibody and instructions for use. A therapeutically effective amount of such an antibody can be used for prophylaxis, treatment or amelioration of Ft infection and for inhibiting Ft uptake by cells in a subject. The antibody can also be used to detect Ft infection. Also disclosed is an isolated nucleic acid molecule encoding the antibody, an expression vector having the isolated nucleic acid molecule, and a host cell transfected with such an expression vector.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
January 5, 2021
Assignee:
THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
Type:
Grant
Filed:
January 8, 2016
Date of Patent:
December 29, 2020
Assignee:
ALK-ABELLO A/S
Inventors:
Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vázquez, Juan Carlos Moreno Segura, Maria José Chamorro Salillas
Abstract: According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a Staphylococcus species target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the Staphylococcus species target antigen with an EC50 of about 10 nM or less, and/or are capable of promoting complement deposition on the Staphylococcus species with an EC50 of about 10 nM.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
December 15, 2020
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Brinda Prasad, Andrew J. Murphy, Karolina Meagher, Peter Mason
Abstract: Method for preparing botulinum neurotoxin and nanoparticle thereof are provided. The method includes fermenting bacteria Clostridium botulinum in a fermentation media free of animal-derived ingredients and contacting the fermentation media with an anion exchange media slurry and obtaining a supernatant including the botulinum neurotoxin by centrifugation. The method further includes dialyzing the supernatant and collecting a dialyzed solution including the botulinum neurotoxin, contacting the dialyzed solution with an anion exchange chromatography column, contacting an elute collected from the anion exchange chromatography column with a cation exchange chromatography column, and collecting an elute. The nanoparticle includes multi-layer including an innermost water phase core including biomolecules encapsulated by an oil phase layer, thereby forming a water-in-oil structure, water phase layers; oil phase layers; and an outmost cream layer.
Abstract: The present invention relates to Salmonella mutant strains and their use as a vaccine for preventing Salmonella infection, in particular in eggs.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
November 24, 2020
Assignee:
Universiteit Gent
Inventors:
Filip Van Immerseel, Ruth Raspoet, Richard Ducatelle
Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
November 24, 2020
Assignee:
ALK-ABELLÓ A/S
Inventors:
Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vázquez, Juan Carlos Moreno Segura, Maria José Chamorro Salillas
Abstract: The invention provides compositions and methods for reducing one or more symptoms of disease by administering compositions comprising SipA. The invention's compositions and methods are particularly advantageous in reducing symptoms of diseases that are associated with overexpression of P-gp and/or p53. The invention's compositions and methods are useful in reducing cancer symptom and/or cancer multidrug resistance (MDR). The invention provides a method for reducing one or more symptoms of cancer in a mammalian subject in need thereof, comprising administering to said subject a composition comprising purified SipA. In one embodiment, said SipA is operably conjugated to a nanoparticle. In another embodiment, said cancer comprises cancer cells resistant to at least one cytotoxin.
Abstract: The present invention is concerned with microorganisms or fragments thereof as sensorically neutral oral care agents, particularly for prevention of dental calculus, as anti-caries agents and/or anti-oral malodor agents. The invention is furthermore concerned with compositions comprising microorganisms or fragments thereof for reducing mutans Streptococci. Such compositions can be used in oral care compositions, e.g. for caries prophylaxis, or for prophylaxis of dental calculus or oral malodor. They may also or instead be used for prevention or treatment of oral malodor. As the microorganisms and fragments thereof according to the present invention have a very low, unobtrusive smell and taste, they are particularly suited as sensorically neutral agents for preventment of dental calculus, caries, oral biofilm formation and/or for prevention or treatment of oral malodor.
Abstract: Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
November 10, 2020
Assignees:
Northwestern University, Cornell University
Inventors:
Michael Christopher Jewett, Jessica Carol Stark, Matthew P. DeLisa, Thapakorn Jaroentomeechai
Abstract: Disclosed herein are materials and methods for achieving sequence-specific organism detection and/or phenotype(s) using sequence-specific oligonucleotides. Also disclosed are related kits, cultures, and cells for detecting and/or phenotyping microorganisms in a sequence-specific manner.
Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
Type:
Grant
Filed:
November 7, 2016
Date of Patent:
September 29, 2020
Assignee:
Pfizer Inc.
Inventors:
Fiona Laichu Lin, Viliam Pavliak, Michael William Pride, Shite Sebastian